Gravar-mail: PSA RESPONSE TO NEOADJUVANT ANDROGEN DEPRIVATION THERAPY IS A STRONG INDEPENDENT PREDICTOR OF SURVIVAL IN HIGH-RISK PROSTATE CANCER IN THE DOSE-ESCALATED RADIATION THERAPY ERA